STEPHEN WANASKI, PHD

Vice President, Research & Exploratory Development

 

Dr. Stephen Wanaski serves as Vice President of Research & Exploratory Development at Paragon Biosciences, overseeing the pharmacology/toxicology and clinical pharmacology development activities for drug candidates across portfolio companies. 

Dr. Wanaski brings a wealth of experience to Paragon including orphan drug development of small and large molecules from discovery through late stage clinical studies and approval. 

Previously, Dr. Wanaski served as Vice President of Research & Exploratory Development at Castle Creek Pharmaceuticals, a Paragon portfolio company.  He held the same role at Marathon Pharmaceuticals playing an integral role in the development and FDA approval of Emflaza® for the treatment of Duchenne muscular dystrophy.  Prior to Marathon, Dr. Wanaski was VP, Research & Development at NeuroTherapeutics Pharma and led scientific and drug discovery efforts of the "virtual" Series A funded company into clinical development and helped to secure over $43MM in Series B venture investment.  He led preclinical and clinical pharmacology development at Ovation Pharmaceuticals (acquired by Lundbeck) and was responsible for late-stage NDA-enabling activities for four, first cycle NDA approvals in various CNS indications (Sabril® for treatment of refractory complex partial seizures and infantile spasms, Onfi® for the treatment of Lennox-Gastaut syndrome, and Carnexiv® as intravenous replacement therapy for oral carbamazepine).  He also worked at an oncology-based biotech company, NeoPharm, across various departments with responsibilities ranging from drug formulations and bioanalytical to translational medicine and biomarker development.

Dr. Wanaski received a B.A. from the University of Notre Dame and earned his Ph.D. in biochemistry from the University of Illinois in Urbana-Champaign.